{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-017544","form_type":"8-K/A","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.508840+00:00","generated_at":"2026-06-05T12:28:42.603548+00:00","sec_items":["2.01","9.01","8.01","1.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Onconetix completes Proteomedix acquisition; target shows $27.2M deficit, going concern","bullets":["Proteomedix 2022 revenue $392K, net loss $2.04M; accumulated deficit $27.2M as of Dec 31, 2022.","Total liabilities $6.86M vs stockholders' deficit $5.79M; cash only $470K at year-end 2022.","Auditor's report includes substantial doubt about Proteomedix's ability to continue as going concern.","Onconetix issued stock for 100% of Proteomedix equity on Dec 15, 2023; acquisition previously disclosed.","Pro forma financials and unaudited interim statements through Sep 30, 2023 now filed with SEC."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-017544","json":"https://secwatch.observer/filing/0001213900-24-017544.json","markdown":"https://secwatch.observer/filing/0001213900-24-017544.md","text":"https://secwatch.observer/filing/0001213900-24-017544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/0001213900-24-017544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/ea0200807-8ka2_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:28:42.603548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"383aab547004759bc01765eff86dca81586bdfbc","claim":"Onconetix, Inc. completed an acquisition involving Proteomedix AG for share exchange (closed 2023-12-15).","evidence_excerpt":"the Company consummated a share exchange transaction (the “ Share Exchange ”) with Proteomedix on December 15, 2023.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/0001213900-24-017544-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Proteomedix AG"},{"label":"Consideration","value":"share exchange"},{"label":"Closing","value":"2023-12-15"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}